<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006081</article-id><article-id pub-id-type="pmc">PMC11859749</article-id><article-id pub-id-type="doi">10.3390/ph18020269</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-18-00269</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Potential of Using Screening Tools for Bipolar Disorder to Predict Lithium Response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Janiri</surname><given-names>Delfina</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-pharmaceuticals-18-00269" ref-type="aff">1</xref><xref rid="af2-pharmaceuticals-18-00269" ref-type="aff">2</xref><xref rid="fn1-pharmaceuticals-18-00269" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8254-9299</contrib-id><name><surname>Pinto</surname><given-names>Mario</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af2-pharmaceuticals-18-00269" ref-type="aff">2</xref><xref rid="fn1-pharmaceuticals-18-00269" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Montanari</surname><given-names>Silvia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceuticals-18-00269" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0004-7959-8419</contrib-id><name><surname>Marzo</surname><given-names>Ester Maria</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-pharmaceuticals-18-00269" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0004-5393-4509</contrib-id><name><surname>Sfratta</surname><given-names>Greta</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-pharmaceuticals-18-00269" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Donofrio</surname><given-names>Guglielmo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-pharmaceuticals-18-00269" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Koukopoulos</surname><given-names>Alexia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af3-pharmaceuticals-18-00269" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8139-9230</contrib-id><name><surname>Camardese</surname><given-names>Giovanni</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-pharmaceuticals-18-00269" ref-type="aff">2</xref><xref rid="af4-pharmaceuticals-18-00269" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6963-7494</contrib-id><name><surname>Simonetti</surname><given-names>Alessio</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-pharmaceuticals-18-00269" ref-type="aff">2</xref><xref rid="af5-pharmaceuticals-18-00269" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Moccia</surname><given-names>Lorenzo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-pharmaceuticals-18-00269" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Autullo</surname><given-names>Gianna</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-pharmaceuticals-18-00269" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9767-8752</contrib-id><name><surname>Sani</surname><given-names>Gabriele</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-pharmaceuticals-18-00269" ref-type="aff">1</xref><xref rid="af2-pharmaceuticals-18-00269" ref-type="aff">2</xref><xref rid="c1-pharmaceuticals-18-00269" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Scarselli</surname><given-names>Marco</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-18-00269"><label>1</label>Department of Neuroscience, Section of Psychiatry, Universit&#x000e0; Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy; <email>delfina.janiri@unicatt.it</email> (D.J.); <email>silvia.montanari@unicatt.it</email> (S.M.); <email>estermarzo7@gmail.com</email> (E.M.M.); <email>sfrattagreta24@gmail.com</email> (G.S.); <email>guglielmodonofrio96@gmail.com</email> (G.D.); <email>lorenzo.moccia@unicatt.it</email> (L.M.)</aff><aff id="af2-pharmaceuticals-18-00269"><label>2</label>Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy; <email>mario.pinto@guest.policlinicogemelli.it</email> (M.P.); <email>g.camardese@unilink.it</email> (G.C.); <email>alessio.simonetti@policlinicogemelli.it</email> (A.S.); <email>gianna.autullo@unicatt.it</email> (G.A.)</aff><aff id="af3-pharmaceuticals-18-00269"><label>3</label>Centro Lucio Bini, ARET&#x000c6;US Onlus, Via Crescenzio 42, 00193 Rome, Italy; <email>alexiakoukopoulos@gmail.com</email></aff><aff id="af4-pharmaceuticals-18-00269"><label>4</label>Department of Life Science, Health, and Health Professions, Link Campus University, 00165 Rome, Italy</aff><aff id="af5-pharmaceuticals-18-00269"><label>5</label>Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX 77030, USA</aff><author-notes><corresp id="c1-pharmaceuticals-18-00269"><label>*</label>Correspondence: <email>gabriele.sani@unicatt.it</email></corresp><fn id="fn1-pharmaceuticals-18-00269"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>18</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue>2</issue><elocation-id>269</elocation-id><history><date date-type="received"><day>17</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>05</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background/Objectives:</bold> Lithium is the gold standard for treating Bipolar Disorder (BD), but its effectiveness varies widely. While clinical and environmental factors may influence response, it remains unclear if screening tools can reliably predict lithium response outcomes. This study explores this potential using two widely used screening instruments for BD. <bold>Methods:</bold> A total of 146 patients with BD were evaluated. Lithium response was assessed using the Alda Scale, while hypomanic and manic symptoms were characterized through the Hypomania Checklist-32 (HCL-32) and the Mood Disorder Questionnaire (MDQ). Group differences in HCL-32 and MDQ scores were analyzed using ANOVA, and a multivariate model was employed to identify predictors of lithium response. <bold>Results:</bold> Of the total sample, 46 (31.5%) patients were identified as lithium responders based on the Alda Scale. Responders exhibited significantly higher HCL-32 scores compared to non-responders (<italic toggle="yes">p</italic> = 0.023), while no differences were observed in MDQ scores or other sociodemographic characteristics. Linear regression analysis revealed that HCL-32 scores were a significant predictor of Alda Scale scores, with no associations found for age, gender, or MDQ scores. <bold>Conclusions:</bold> Our study underscores the importance of considering hypomanic symptoms when estimating lithium response in BD, particularly by utilizing the HCL-32 during screening.</p></abstract><kwd-group><kwd>lithium</kwd><kwd>screening</kwd><kwd>bipolar disorder</kwd><kwd>hypomania</kwd><kwd>mania</kwd><kwd>treatment response</kwd><kwd>Alda scale</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-18-00269"><title>1. Introduction</title><p>Lithium remains the gold standard for treating Bipolar Disorder (BD), yet its effectiveness varies significantly across patients. Approximately 30% of individuals treated with lithium are classified as &#x0201c;excellent responders&#x0201d;, while others show a range of reduced responses [<xref rid="B1-pharmaceuticals-18-00269" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceuticals-18-00269" ref-type="bibr">2</xref>]. The most widely adopted and validated method to assess lithium response is the Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder, commonly referred to as the Alda Scale, named after its creator, Martin Alda [<xref rid="B3-pharmaceuticals-18-00269" ref-type="bibr">3</xref>]. The variability in lithium response, even when accounting for potential issues with treatment adherence, highlights the urgent need for reliable predictors of response to personalize treatment strategies and improve clinical outcomes.</p><p>Patients who respond well to lithium often display distinct phenotypic traits. These include specific clinical features, such as a mania&#x02013;depression&#x02013;interval cycle without rapid cycling, a family history of BD&#x02014;especially among relatives who also responded well to lithium&#x02014;and a shorter illness duration prior to starting lithium treatment [<xref rid="B4-pharmaceuticals-18-00269" ref-type="bibr">4</xref>]. Other significant factors, such as the number of hospitalizations before treatment, have also been identified [<xref rid="B5-pharmaceuticals-18-00269" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceuticals-18-00269" ref-type="bibr">6</xref>]. Notably, their response to treatment tends to remain stable over time. Recent studies employing machine learning methods have partially replicated these clinical findings, highlighting additional key variables such as age at first diagnosis, age at first treatment, and the interval between these events as predictors of lithium responsiveness [<xref rid="B7-pharmaceuticals-18-00269" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceuticals-18-00269" ref-type="bibr">8</xref>]. Furthermore, temperament styles and environmental factors, such as childhood abuse, have been shown to influence lithium treatment outcomes [<xref rid="B9-pharmaceuticals-18-00269" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceuticals-18-00269" ref-type="bibr">10</xref>]. Hyperthymic and irritable temperaments are associated with better responses, whereas histories of physical or emotional abuse negatively affect outcomes [<xref rid="B10-pharmaceuticals-18-00269" ref-type="bibr">10</xref>]. These factors likely influence both the pathophysiology of BD and adherence to treatment, ultimately shaping its effectiveness [<xref rid="B11-pharmaceuticals-18-00269" ref-type="bibr">11</xref>].</p><p>While clinical predictors of lithium response have been extensively studied, it remains unclear whether screening tools for BD can serve as quantitative instruments to predict treatment outcomes. Two of the most widely used tools for the early identification and characterization of mood disorders, including BD, are the Mood Disorder Questionnaire (MDQ; [<xref rid="B12-pharmaceuticals-18-00269" ref-type="bibr">12</xref>]) and the Hypomania Checklist-32 (HCL-32; [<xref rid="B13-pharmaceuticals-18-00269" ref-type="bibr">13</xref>]). These tools are well-established for detecting BD and demonstrate strong overall diagnostic accuracy [<xref rid="B14-pharmaceuticals-18-00269" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceuticals-18-00269" ref-type="bibr">15</xref>]. However, no definitive evidence has yet linked the results of these instruments to lithium response.</p><p>Given the variability in lithium response, tools and guidelines that improve the prediction of positive outcomes are invaluable for clinicians and patients [<xref rid="B16-pharmaceuticals-18-00269" ref-type="bibr">16</xref>]. This study aimed to investigate whether the MDQ and HCL-32, the primary screening instruments for BD, could also serve as predictors of lithium response.</p></sec><sec sec-type="results" id="sec2-pharmaceuticals-18-00269"><title>2. Results</title><p>In the total sample, 76 participants were male (52%), and 70 were female (48%). The mean age was 43.78 years (SD = 12.33), and the mean education level was 14.38 years (SD = 4.20). The classification of participants in our study, based on their response to lithium treatment according to the Alda Scale criteria, identified 46 (31.5%) patients as treatment Responders (mean TS = 7.46, SD = 0.66) and 100 (68.5%) patients as Non-Responders (mean TS = 2.92, SD = 1.76). Sociodemographic and clinical characteristics of the sample are shown in <xref rid="pharmaceuticals-18-00269-t001" ref-type="table">Table 1</xref>.</p><p>The two groups of patients did not differ in their sociodemographic and clinical characteristics, except for the alternative treatments, which were higher for the Lithium Non-Responders group (see <xref rid="pharmaceuticals-18-00269-t001" ref-type="table">Table 1</xref>). Regarding the screening assessment, the two groups of patients presented with a significant difference in the HCL-32 scores [F(1, 144) = 4.84, <italic toggle="yes">p</italic> = 0.023, &#x003b7;<sup>2</sup>&#x0209a; = 0.051; Levene&#x02019;s Test for Equality of Variances: <italic toggle="yes">p</italic> = 0.600], highlighting that patients classified as Lithium Responders had higher scores on the HCL-32 compared to patients classified as Lithium Non-Responders (<xref rid="pharmaceuticals-18-00269-f001" ref-type="fig">Figure 1</xref>a). Conversely, the results showed no difference in the scores of MDQ between the two group of patients [F(1, 44) = 0.70, <italic toggle="yes">p</italic> = 0.403, &#x003b7;<sup>2</sup>&#x0209a; = 0.005; Levene&#x02019;s Test for Equality of Variances: <italic toggle="yes">p</italic> = 0.765] (<xref rid="pharmaceuticals-18-00269-f001" ref-type="fig">Figure 1</xref>b).</p><p>The linear regression analysis conducted on the Alda Scale total scores revealed a significant regression model [F(4, 145) = 2.87, <italic toggle="yes">p</italic> = 0.023], which explained a significant portion of the variance in the scores obtained (R<sup>2</sup> = 0.074, Adjusted R<sup>2</sup> = 0.056). In detail, only the HCL-32 scores were found to be a significant direct predictor (&#x003b2; = 0.342, t = 3.260, <italic toggle="yes">p</italic> = 0.001; see <xref rid="pharmaceuticals-18-00269-f002" ref-type="fig">Figure 2</xref>c), showing that higher scores obtained in the HCL-32 predicted higher scores obtained in the Alda Scale. By contrast, no significant association was found with gender (&#x003b2; = &#x02212;0.159, t = &#x02212;0.381, <italic toggle="yes">p</italic> = 0.704, see <xref rid="pharmaceuticals-18-00269-f002" ref-type="fig">Figure 2</xref>a), age (&#x003b2; = 0.077, t = 0.925, <italic toggle="yes">p</italic> = 0.356; see <xref rid="pharmaceuticals-18-00269-f002" ref-type="fig">Figure 2</xref>b) or MDQ scores (&#x003b2; = &#x02212;0.151, t = &#x02212;1.466, <italic toggle="yes">p</italic> = 0.145; see <xref rid="pharmaceuticals-18-00269-f002" ref-type="fig">Figure 2</xref>d).</p><p>In our regression analyses, The Mahalanobis Distance was smaller than the critical value (all <italic toggle="yes">p</italic>&#x02009; &#x0003e; &#x02009;0.001, critical value recommended by Tabachnick et al. [<xref rid="B17-pharmaceuticals-18-00269" ref-type="bibr">17</xref>]) indicating that in our set of data, no multivariate outliers were present. In addition, we found that the distribution of variables was comparable to a multivariate normal distribution (Mardia&#x02019;s multivariate kurtosis index&#x02009; = &#x02009;15.21; reference value&#x02009; = &#x02009;24; [<xref rid="B18-pharmaceuticals-18-00269" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceuticals-18-00269" ref-type="bibr">19</xref>]).</p><p>Regarding multicollinearity, the obtained values in this study (Age: Tolerance = 0.953, VIF = 1.050; Gender: Tolerance = 0.999, VIF = 1.001; HCL: Tolerance = 0.595, VIF = 1.680; MDQ: Tolerance = 0.616, VIF = 1.624) were all above 0.10 for Tolerance, indicating low multicollinearity, and the VIF values for the independent variables were below 4, suggesting no significant collinearity issues.</p></sec><sec sec-type="discussion" id="sec3-pharmaceuticals-18-00269"><title>3. Discussion</title><p>The aim of our study was to assess whether clinical tools commonly used for psychopathological screening in the diagnosis of bipolar disorder, specifically the Mood Disorder Questionnaire (MDQ) and the Hypomania Checklist-32 (HCL-32), could also serve as predictive variables for a positive response to lithium treatment.</p><p>Our findings revealed that the Lithium Responder group scored significantly higher on the HCL-32 compared to the Non-Responder group, while no significant differences were observed in MDQ scores between the two groups. Furthermore, regression analysis demonstrated a significant predictive relationship between the HCL-32 and lithium response. Specifically, patients with more hypomanic symptoms achieved higher scores on the Alda Scale, indicating a strong association between HCL-32 scores and lithium responsiveness (<italic toggle="yes">p</italic> = 0.023).</p><p>These findings align with previous research emphasizing the link between manic/hypomanic features and improved lithium response. Earlier studies have demonstrated that patients with a manic&#x02013;depressive interval (MDI) type of cycle are more likely to respond favorably to lithium treatment [<xref rid="B4-pharmaceuticals-18-00269" ref-type="bibr">4</xref>,<xref rid="B9-pharmaceuticals-18-00269" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceuticals-18-00269" ref-type="bibr">10</xref>]. In parallel, patients with an MDI cycle tend to exhibit more pronounced manic/hypomanic symptoms compared to patients with a depressive&#x02013;manic interval (DMI) cycle, who generally experience less manic morbidity during long-term follow-up but show reduced responsiveness to lithium [<xref rid="B20-pharmaceuticals-18-00269" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceuticals-18-00269" ref-type="bibr">21</xref>]. Our results also align with lithium&#x02019;s well-established antimanic effects. Lithium is particularly effective when initiated during a manic or hypomanic phase, serving as a protective factor against subsequent depressive episodes in individuals with MDI cycles [<xref rid="B20-pharmaceuticals-18-00269" ref-type="bibr">20</xref>,<xref rid="B22-pharmaceuticals-18-00269" ref-type="bibr">22</xref>]. A recent study conducted by our group also found that a hyperthymic temperament predicts a favorable response to lithium treatment [<xref rid="B10-pharmaceuticals-18-00269" ref-type="bibr">10</xref>], supporting previous research that identified a positive correlation between lithium response and hyperthymic temperament [<xref rid="B23-pharmaceuticals-18-00269" ref-type="bibr">23</xref>]. Notably, hyperthymic traits are often linked to a predominant manic/hypomanic polarity [<xref rid="B24-pharmaceuticals-18-00269" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceuticals-18-00269" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceuticals-18-00269" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceuticals-18-00269" ref-type="bibr">27</xref>], which, in turn, predicts a positive lithium response phenotype [<xref rid="B25-pharmaceuticals-18-00269" ref-type="bibr">25</xref>]. These results are consistent with the long-standing view of lithium&#x02019;s primary antimanic effect, first observed by Cade [<xref rid="B28-pharmaceuticals-18-00269" ref-type="bibr">28</xref>], and align with the association we found in the current study between higher scores on the Alda Scale and the HCL-32. Moreover, previous research suggests that lithium may influence gene expression, acting as a neurotrophic factor [<xref rid="B29-pharmaceuticals-18-00269" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceuticals-18-00269" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceuticals-18-00269" ref-type="bibr">31</xref>]. Interestingly, other studies have reported a link between genes associated with manic predominant polarity and hyperthymic temperament [<xref rid="B32-pharmaceuticals-18-00269" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceuticals-18-00269" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceuticals-18-00269" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceuticals-18-00269" ref-type="bibr">35</xref>]. Future investigations should therefore further explore the promising yet still preliminary results obtained so far from genetic studies on lithium response in bipolar patients. [<xref rid="B36-pharmaceuticals-18-00269" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceuticals-18-00269" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceuticals-18-00269" ref-type="bibr">38</xref>].</p><p>The strong association between HCL-32 scores and lithium responsiveness may be attributed to the tool&#x02019;s sensitivity to manic and hypomanic polarity. These components of bipolar disorder&#x02014;characterized by impulsivity, overactivity, elevated mood, and increased energy&#x02014;are effectively captured by the HCL-32 [<xref rid="B13-pharmaceuticals-18-00269" ref-type="bibr">13</xref>,<xref rid="B39-pharmaceuticals-18-00269" ref-type="bibr">39</xref>], which has demonstrated robust diagnostic sensitivity. In contrast, our study found no predictive relationship between MDQ scores and lithium responsiveness. This discrepancy may be explained by the broader scope of MDQ items, some of which can reflect conditions beyond bipolar disorder, such as anxiety, trauma-related disorders, substance use disorders, eating disorders, and impulse control disorders [<xref rid="B40-pharmaceuticals-18-00269" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceuticals-18-00269" ref-type="bibr">41</xref>]. Previous studies have highlighted this limitation by identifying a two-factor structure within the MDQ, consisting of Positive Activation and Negative Activation dimensions [<xref rid="B42-pharmaceuticals-18-00269" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceuticals-18-00269" ref-type="bibr">43</xref>]. The Positive Activation subscale&#x02014;which includes symptoms such as increased energy, grandiosity, and decreased need for sleep&#x02014;is specific to bipolar disorder. In contrast, the Negative Activation subscale&#x02014;encompassing symptoms like irritability, racing thoughts, negative emotional states, and distractibility&#x02014;is more broadly associated with emotion dysregulation and transdiagnostic personality traits [<xref rid="B42-pharmaceuticals-18-00269" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceuticals-18-00269" ref-type="bibr">43</xref>]. While the MDQ remains a valuable screening tool for bipolar disorder, its predictive value for lithium response may be limited by its reduced specificity for manic polarity.</p><p>Our study, along with the existing literature, highlights the distinct qualities of the HCL-32 and MDQ in predicting lithium response. The HCL-32, with its sensitivity to manic traits, is better for identifying patients likely to respond to lithium. In contrast, the MDQ&#x02019;s broader scope makes it a useful screening tool, though less specific for lithium response. These findings emphasize the importance of personalized treatment, suggesting that detailed clinical phenotypes may offer more insight into lithium response than traditional diagnostic categories [<xref rid="B44-pharmaceuticals-18-00269" ref-type="bibr">44</xref>] and could lead to more tailored and effective pharmacological strategies.</p><p>Before presenting the conclusions, we must acknowledge certain limitations that may affect the generalizability of our findings. First, the cross-sectional design of our study limits our ability to establish causal relationships. However, we mitigated this limitation by using a multivariate model to predict lithium response. Second, clinical variables and treatment response were assessed retrospectively. Nevertheless, we employed the Alda Scale, which is considered the gold standard for evaluating lithium response [<xref rid="B45-pharmaceuticals-18-00269" ref-type="bibr">45</xref>]. Furthermore, to reduce the risk of recall bias, we gathered information not only from patient reports but also from family members and close friends (who were present at least at one visit) and reviewed all available medical records. Additionally, the study population was limited to outpatients from a single clinical site, so the results may not be widely applicable. Nonetheless, this study represents the first attempt to consider screening tools for BD as predictors of lithium response.</p><p>The results of our study may have important therapeutic implications in the future. The significant predictive value of the Hypomania Checklist-32 for lithium treatment response could enable more personalized treatment plans. Future studies could expand on these findings, focusing on improving the use of psychometric tools for predicting lithium response, particularly emphasizing the importance of manic polarity in treatment stratification. Additionally, future research could explore the integration of psychopathological tools with biological markers, such as genetic biomarkers. These findings support the growing effort to optimize treatment approaches for bipolar disorder through accurate phenotypic and psychometric assessments.</p></sec><sec id="sec4-pharmaceuticals-18-00269"><title>4. Materials and Methods</title><sec sec-type="subjects" id="sec4dot1-pharmaceuticals-18-00269"><title>4.1. Participants</title><p>We enrolled 146 outpatients with DSM-5 diagnoses of BD type I and BD type II. Patients were recruited from the Psychiatry Department of the Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy. Diagnosis was confirmed using the Structured Clinical Interview for DSM-5 [<xref rid="B46-pharmaceuticals-18-00269" ref-type="bibr">46</xref>]. In addition to a DSM-5 diagnosis of BD, inclusion criteria were as follows: (a) age 18&#x02013;65 years; (b) at least 5 years of education; (c) fluency in Italian; (d) stable pharmacological treatment with lithium for at least 3 months. Exclusion criteria were (a) a history of psychosis not related to the primary mood disorder; (b) traumatic brain injury with loss of consciousness; (c) major medical or neurological conditions; (d) a Mini-Mental State Examination (MMSE) score of less than 24 (since scores below this level indicate cognitive deterioration based on normative data from the Italian population); (e) current substance use disorder. Patients were in clinical remission according to the Young Mania Rating Scale (YMRS) for manic symptoms and the 17-item Hamilton Rating Scale for Depression (HAMD) for depressive symptoms.</p><p>The study adhered to the Principles of Human Rights established by the World Medical Association (WMA) at the 18th General Assembly in Helsinki, Finland (June 1964), and subsequently revised at the 64th General Assembly in Fortaleza, Brazil (October 2013). All participants provided written informed consent after receiving a comprehensive explanation of the objectives and procedures of the study. No financial compensation was offered to participants. The research followed strict ethical standards, ensuring full protection of participants&#x02019; rights and well-being. This adherence to ethical principles, combined with thorough diagnostic procedures, reinforces both the scientific rigor and ethical integrity of the study, enhancing the validity and reliability of its findings. The study received approval from local ethics committees (protocol number: 5016, 23 January 2023).</p></sec><sec id="sec4dot2-pharmaceuticals-18-00269"><title>4.2. Clinical and Psychopathological Assessment</title><p>A semi-structured interview, used in prior studies [<xref rid="B47-pharmaceuticals-18-00269" ref-type="bibr">47</xref>], was employed to collect comprehensive data on anamnestic characteristics and clinical information. Administered by an experienced psychiatrist, the interview adhered to DSM-5 criteria and clinical assessments, avoiding simplistic yes/no responses to ensure more nuanced insights. The wording of questions was flexible for clarity, and the final evaluation incorporated input not only from the patients but also from family members or close friends (who were present for at least one visit) and relevant medical records.</p><p>To characterize bipolar disorders [<xref rid="B15-pharmaceuticals-18-00269" ref-type="bibr">15</xref>], two additional tools were administered: the Hypomania Symptom Checklist-32 (HCL-32) and the Mood Disorder Questionnaire (MDQ).</p><p>The HCL-32 is a self-report questionnaire commonly used to detect hypomanic symptoms, particularly in individuals with bipolar spectrum disorders [<xref rid="B13-pharmaceuticals-18-00269" ref-type="bibr">13</xref>,<xref rid="B39-pharmaceuticals-18-00269" ref-type="bibr">39</xref>]. It consists of 32 items that evaluate behaviors and experiences associated with elevated mood, increased energy, overactivity, and impulsivity. Participants respond in a dichotomous format (yes/no) based on whether they have experienced specific symptoms during their &#x0201c;highs&#x0201d;. A total score is calculated by summing the &#x0201c;yes&#x0201d; responses, with higher scores suggesting a greater likelihood of bipolarity. The commonly used cut-off is &#x02265;14, though thresholds may vary depending on the clinical or research context.</p><p>The MDQ is a 15-item self-report screening instrument designed to identify individuals most likely to have bipolar disorder [<xref rid="B12-pharmaceuticals-18-00269" ref-type="bibr">12</xref>,<xref rid="B48-pharmaceuticals-18-00269" ref-type="bibr">48</xref>]. It includes 13 yes/no questions about manic or hypomanic symptoms, a question on symptom co-occurrence, and one assessing symptom-related functional impairment. It is particularly useful in distinguishing bipolar disorder from other mood disturbances. A positive screening result typically requires a &#x0201c;yes&#x0201d; to at least 7 out of 13 symptoms, symptom co-occurrence, and moderate or severe functional impairment.</p></sec><sec id="sec4dot3-pharmaceuticals-18-00269"><title>4.3. Lithium Response Assessment</title><p>To assess the response to lithium treatment, we employed the Alda Scale, which is specifically designed for the retrospective evaluation of prophylactic treatment responses in naturalistic settings. The instrument consists of two subscales, labeled A and B. The A scale, which ranges from 0 to 10, measures the degree of improvement attributed to lithium treatment, including reductions in the frequency of recurrences and residual symptoms, among other factors. The B scale contains five criteria, each rated from 0 to 2, with higher scores indicating a greater likelihood that external factors may have influenced the observed improvements. The five potential confounding factors in the B scale are as follows: (B1) number of episodes before or off treatment, (B2) frequency of episodes before or off treatment, (B3) duration of lithium treatment, (B4) compliance during periods of stability, and (B5) use of additional medication during periods of stability. The total score (TS) on the Alda Scale is calculated by subtracting the B score from the A score. If the B score exceeds the A score, resulting in a negative value, it is recorded as 0.</p><p>In accordance with Manchia et al. [<xref rid="B45-pharmaceuticals-18-00269" ref-type="bibr">45</xref>], a TS value of 7 or higher was considered indicative of a respondent phenotype. Although the Alda scale was originally designed to evaluate long-term treatment responses, we chose to include participants with less than one year of lithium treatment in our study. This decision was made because the scale accounts for potential bias due to treatment duration under Criterion B3. It is important to note that only a small proportion (2.5%) of our sample had been receiving lithium treatment for less than a year.</p></sec><sec id="sec4dot4-pharmaceuticals-18-00269"><title>4.4. Statistical Analyses</title><p>First, we divided our sample into two groups: Lithium Responders and Lithium Non-Responders, based on the Alda Scale cut-off (TS &#x02265; 7 indicating good lithium responders).</p><p>Second, we conducted a series of Chi-Squared Tests and one-way ANOVAs with lithium response as the independent variable and sociodemographic and clinical variables and the scores obtained on the screening assessment (HCL-32 or MDQ) as the dependent variables. The aim was to evaluate potential differences in these variables between patient groups classified as Responders or Non-Responders to lithium treatment. Significance was set at <italic toggle="yes">p</italic> = 0.05. To account for multiple comparisons and reduce the likelihood of Type I errors, a Bonferroni correction was applied to the results (adjusted <italic toggle="yes">p</italic>-value: <italic toggle="yes">p</italic> &#x0003c; 0.05/number of comparisons).</p><p>Third, we conducted a linear regression analysis to assess the contribution of HCL-32 and MDQ scores as predictor variables for lithium response. The TS obtained on the Alda Scale was used as the dependent variable, while the HCL-32 and MDQ scores, together with age and gender, were included as independent variables. This approach allowed us to explore the influence of each predictor on the responses of patients to lithium treatment, as assessed by the Alda Scale. Multivariate normality in the regression analyses was regularly assessed [<xref rid="B49-pharmaceuticals-18-00269" ref-type="bibr">49</xref>]. Multicollinearity between the predictor variables was assessed using Tolerance and VIF values. All statistical analyses were performed using JASP (Version 0.19.1; JASP Team, 2024) and SPSS (Version 29.0.1.0; IBM Corp, Armonk, NY, USA, 2023).</p></sec></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, D.J.; Data curation, M.P. and S.M.; Formal analysis, M.P.; Investigation, S.M., E.M.M., G.S. (Greta Sfratta), and G.D.; Methodology, D.J. and M.P.; Project administration, G.S. (Gabriele Sani); Resources, D.J. and G.S. (Gabriele Sani); Software, M.P. and S.M.; Supervision, D.J., A.K., G.C., A.S., L.M., G.A. and G.S. (Gabriele Sani); Validation, D.J., M.P. and S.M.; Visualization, D.J. and M.P.; Writing&#x02014;original draft, M.P., E.M.M., G.S. (Greta Sfratta), and G.D.; Writing&#x02014;review and editing, D.J. and S.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Fondazione Policlinico Agostino Gemelli IRCCS (protocol number: 5016, date of approval: 23 January 2023).</p></notes><notes><title>Informed Consent Statement</title><p>Written informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on request from the corresponding author due to ethical reasons.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceuticals-18-00269"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garnham</surname><given-names>J.</given-names></name>
<name><surname>Munro</surname><given-names>A.</given-names></name>
<name><surname>Slaney</surname><given-names>C.</given-names></name>
<name><surname>Macdougall</surname><given-names>M.</given-names></name>
<name><surname>Passmore</surname><given-names>M.</given-names></name>
<name><surname>Duffy</surname><given-names>A.</given-names></name>
<name><surname>O&#x02019;Donovan</surname><given-names>C.</given-names></name>
<name><surname>Teehan</surname><given-names>A.</given-names></name>
<name><surname>Alda</surname><given-names>M.</given-names></name>
</person-group><article-title>Prophylactic treatment response in bipolar disorder: Results of a naturalistic observation study</article-title><source>J. Affect. Disord.</source><year>2007</year><volume>104</volume><fpage>185</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2007.03.003</pub-id><pub-id pub-id-type="pmid">17442400</pub-id>
</element-citation></ref><ref id="B2-pharmaceuticals-18-00269"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alda</surname><given-names>M.</given-names></name>
</person-group><article-title>Who are excellent lithium responders and why do they matter?</article-title><source>World Psychiatry</source><year>2017</year><volume>16</volume><fpage>319</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1002/wps.20462</pub-id><pub-id pub-id-type="pmid">28941103</pub-id>
</element-citation></ref><ref id="B3-pharmaceuticals-18-00269"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grof</surname><given-names>P.</given-names></name>
<name><surname>Duffy</surname><given-names>A.</given-names></name>
<name><surname>Cavazzoni</surname><given-names>P.</given-names></name>
<name><surname>Grof</surname><given-names>E.</given-names></name>
<name><surname>Garnham</surname><given-names>J.</given-names></name>
<name><surname>MacDougall</surname><given-names>M.</given-names></name>
<name><surname>O&#x02019;Donovan</surname><given-names>C.</given-names></name>
<name><surname>Alda</surname><given-names>M.</given-names></name>
</person-group><article-title>Is response to prophylactic lithium a familial trait?</article-title><source>J. Clin. Psychiatry</source><year>2002</year><volume>63</volume><fpage>942</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.4088/JCP.v63n1013</pub-id><pub-id pub-id-type="pmid">12416605</pub-id>
</element-citation></ref><ref id="B4-pharmaceuticals-18-00269"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hui</surname><given-names>T.P.</given-names></name>
<name><surname>Kandola</surname><given-names>A.</given-names></name>
<name><surname>Shen</surname><given-names>L.</given-names></name>
<name><surname>Lewis</surname><given-names>G.</given-names></name>
<name><surname>Osborn</surname><given-names>D.P.J.</given-names></name>
<name><surname>Geddes</surname><given-names>J.R.</given-names></name>
<name><surname>Hayes</surname><given-names>J.F.</given-names></name>
</person-group><article-title>A systematic review and meta-analysis of clinical predictors of lithium response in bipolar disorder</article-title><source>Acta Psychiatr. Scand.</source><year>2019</year><volume>140</volume><fpage>94</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1111/acps.13062</pub-id><pub-id pub-id-type="pmid">31218667</pub-id>
</element-citation></ref><ref id="B5-pharmaceuticals-18-00269"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kleindienst</surname><given-names>N.</given-names></name>
<name><surname>Engel</surname><given-names>R.</given-names></name>
<name><surname>Greil</surname><given-names>W.</given-names></name>
</person-group><article-title>Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders</article-title><source>Bipolar Disord.</source><year>2005</year><volume>7</volume><fpage>404</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1111/j.1399-5618.2005.00244.x</pub-id><pub-id pub-id-type="pmid">16176433</pub-id>
</element-citation></ref><ref id="B6-pharmaceuticals-18-00269"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grillault Laroche</surname><given-names>D.</given-names></name>
<name><surname>Etain</surname><given-names>B.</given-names></name>
<name><surname>Severus</surname><given-names>E.</given-names></name>
<name><surname>Scott</surname><given-names>J.</given-names></name>
<name><surname>Bellivier</surname><given-names>F.</given-names></name>
</person-group><article-title>ISBD-IGSLI Joint Task Force on Lithium Treatment Socio-demographic and clinical predictors of outcome to long-term treatment with lithium in bipolar disorders: A systematic review of the contemporary literature and recommendations from the ISBD/IGSLI Task Force on treatment with lithium</article-title><source>Int. J. Bipolar Disord.</source><year>2020</year><volume>8</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.1186/s40345-020-00203-3</pub-id><pub-id pub-id-type="pmid">33330966</pub-id>
</element-citation></ref><ref id="B7-pharmaceuticals-18-00269"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nunes</surname><given-names>A.</given-names></name>
<name><surname>Ardau</surname><given-names>R.</given-names></name>
<name><surname>Bergh&#x000f6;fer</surname><given-names>A.</given-names></name>
<name><surname>Bocchetta</surname><given-names>A.</given-names></name>
<name><surname>Chillotti</surname><given-names>C.</given-names></name>
<name><surname>Deiana</surname><given-names>V.</given-names></name>
<name><surname>Garnham</surname><given-names>J.</given-names></name>
<name><surname>Grof</surname><given-names>E.</given-names></name>
<name><surname>Hajek</surname><given-names>T.</given-names></name>
<name><surname>Manchia</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Prediction of lithium response using clinical data</article-title><source>Acta Psychiatr. Scand.</source><year>2020</year><volume>141</volume><fpage>131</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1111/acps.13122</pub-id><pub-id pub-id-type="pmid">31667829</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-18-00269"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hayes</surname><given-names>J.F.</given-names></name>
<name><surname>Ben Abdesslem</surname><given-names>F.</given-names></name>
<name><surname>Eloranta</surname><given-names>S.</given-names></name>
<name><surname>Osborn</surname><given-names>D.P.J.</given-names></name>
<name><surname>Boman</surname><given-names>M.</given-names></name>
</person-group><article-title>Predicting maintenance lithium response for bipolar disorder from electronic health records-a retrospective study</article-title><source>PeerJ</source><year>2024</year><volume>12</volume><fpage>e17841</fpage><pub-id pub-id-type="doi">10.7717/peerj.17841</pub-id><pub-id pub-id-type="pmid">39421428</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-18-00269"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Etain</surname><given-names>B.</given-names></name>
<name><surname>Lajnef</surname><given-names>M.</given-names></name>
<name><surname>Brichant-Petitjean</surname><given-names>C.</given-names></name>
<name><surname>Geoffroy</surname><given-names>P.A.</given-names></name>
<name><surname>Henry</surname><given-names>C.</given-names></name>
<name><surname>Gard</surname><given-names>S.</given-names></name>
<name><surname>Kahn</surname><given-names>J.P.</given-names></name>
<name><surname>Leboyer</surname><given-names>M.</given-names></name>
<name><surname>Young</surname><given-names>A.H.</given-names></name>
<name><surname>Bellivier</surname><given-names>F.</given-names></name>
</person-group><article-title>Childhood trauma and mixed episodes are associated with poor response to lithium in bipolar disorders</article-title><source>Acta Psychiatr. Scand.</source><year>2017</year><volume>135</volume><fpage>319</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1111/acps.12684</pub-id><pub-id pub-id-type="pmid">27987204</pub-id>
</element-citation></ref><ref id="B10-pharmaceuticals-18-00269"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Janiri</surname><given-names>D.</given-names></name>
<name><surname>Simonetti</surname><given-names>A.</given-names></name>
<name><surname>Luciano</surname><given-names>M.</given-names></name>
<name><surname>Montanari</surname><given-names>S.</given-names></name>
<name><surname>Bernardi</surname><given-names>E.</given-names></name>
<name><surname>Carr&#x000e0;</surname><given-names>G.</given-names></name>
<name><surname>Fiorillo</surname><given-names>A.</given-names></name>
<name><surname>Sani</surname><given-names>G.</given-names></name>
</person-group><article-title>Type of cycle, temperament and childhood trauma are associated with lithium response in patients with bipolar disorders</article-title><source>Int. J. Bipolar Disord.</source><year>2024</year><volume>12</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/s40345-024-00331-0</pub-id><pub-id pub-id-type="pmid">38563884</pub-id>
</element-citation></ref><ref id="B11-pharmaceuticals-18-00269"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wrobel</surname><given-names>A.L.</given-names></name>
<name><surname>Jayasinghe</surname><given-names>A.</given-names></name>
<name><surname>Russell</surname><given-names>S.E.</given-names></name>
<name><surname>Marx</surname><given-names>W.</given-names></name>
<name><surname>Alameda</surname><given-names>L.</given-names></name>
<name><surname>Dean</surname><given-names>O.M.</given-names></name>
<name><surname>Cotton</surname><given-names>S.M.</given-names></name>
<name><surname>Berk</surname><given-names>M.</given-names></name>
<name><surname>Turner</surname><given-names>A.</given-names></name>
</person-group><article-title>The influence of childhood trauma on the treatment outcomes of pharmacological and/or psychological interventions for adolescents and adults with bipolar disorder: A systematic review and meta-analysis</article-title><source>J. Affect. Disord.</source><year>2022</year><volume>296</volume><fpage>350</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2021.09.103</pub-id><pub-id pub-id-type="pmid">34606813</pub-id>
</element-citation></ref><ref id="B12-pharmaceuticals-18-00269"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hirschfeld</surname><given-names>R.M.</given-names></name>
<name><surname>Williams</surname><given-names>J.B.</given-names></name>
<name><surname>Spitzer</surname><given-names>R.L.</given-names></name>
<name><surname>Calabrese</surname><given-names>J.R.</given-names></name>
<name><surname>Flynn</surname><given-names>L.</given-names></name>
<name><surname>Keck</surname><given-names>P.E.</given-names></name>
<name><surname>Lewis</surname><given-names>L.</given-names></name>
<name><surname>McElroy</surname><given-names>S.L.</given-names></name>
<name><surname>Post</surname><given-names>R.M.</given-names></name>
<name><surname>Rapport</surname><given-names>D.J.</given-names></name>
<etal/>
</person-group><article-title>Development and validation of a screening instrument for bipolar spectrum disorder: The Mood Disorder Questionnaire</article-title><source>Am. J. Psychiatry</source><year>2000</year><volume>157</volume><fpage>1873</fpage><lpage>1875</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.157.11.1873</pub-id><pub-id pub-id-type="pmid">11058490</pub-id>
</element-citation></ref><ref id="B13-pharmaceuticals-18-00269"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Angst</surname><given-names>J.</given-names></name>
<name><surname>Adolfsson</surname><given-names>R.</given-names></name>
<name><surname>Benazzi</surname><given-names>F.</given-names></name>
<name><surname>Gamma</surname><given-names>A.</given-names></name>
<name><surname>Hantouche</surname><given-names>E.</given-names></name>
<name><surname>Meyer</surname><given-names>T.D.</given-names></name>
<name><surname>Skeppar</surname><given-names>P.</given-names></name>
<name><surname>Vieta</surname><given-names>E.</given-names></name>
<name><surname>Scott</surname><given-names>J.</given-names></name>
</person-group><article-title>The HCL-32: Towards a self-assessment tool for hypomanic symptoms in outpatients</article-title><source>J. Affect. Disord.</source><year>2005</year><volume>88</volume><fpage>217</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2005.05.011</pub-id><pub-id pub-id-type="pmid">16125784</pub-id>
</element-citation></ref><ref id="B14-pharmaceuticals-18-00269"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rybakowski</surname><given-names>J.K.</given-names></name>
<name><surname>Dudek</surname><given-names>D.</given-names></name>
<name><surname>Pawlowski</surname><given-names>T.</given-names></name>
<name><surname>Lojko</surname><given-names>D.</given-names></name>
<name><surname>Siwek</surname><given-names>M.</given-names></name>
<name><surname>Kiejna</surname><given-names>A.</given-names></name>
</person-group><article-title>Use of the Hypomania Checklist-32 and the Mood Disorder Questionnaire for detecting bipolarity in 1051 patients with major depressive disorder</article-title><source>Eur. Psychiatry J. Assoc. Eur. Psychiatr.</source><year>2012</year><volume>27</volume><fpage>577</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1016/j.eurpsy.2010.12.001</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-18-00269"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carvalho</surname><given-names>A.F.</given-names></name>
<name><surname>Takwoingi</surname><given-names>Y.</given-names></name>
<name><surname>Sales</surname><given-names>P.M.G.</given-names></name>
<name><surname>Soczynska</surname><given-names>J.K.</given-names></name>
<name><surname>K&#x000f6;hler</surname><given-names>C.A.</given-names></name>
<name><surname>Freitas</surname><given-names>T.H.</given-names></name>
<name><surname>Quevedo</surname><given-names>J.</given-names></name>
<name><surname>Hyphantis</surname><given-names>T.N.</given-names></name>
<name><surname>McIntyre</surname><given-names>R.S.</given-names></name>
<name><surname>Vieta</surname><given-names>E.</given-names></name>
</person-group><article-title>Screening for bipolar spectrum disorders: A comprehensive meta-analysis of accuracy studies</article-title><source>J. Affect. Disord.</source><year>2015</year><volume>172</volume><fpage>337</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2014.10.024</pub-id><pub-id pub-id-type="pmid">25451435</pub-id>
</element-citation></ref><ref id="B16-pharmaceuticals-18-00269"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Volkmann</surname><given-names>C.</given-names></name>
<name><surname>Bschor</surname><given-names>T.</given-names></name>
<name><surname>K&#x000f6;hler</surname><given-names>S.</given-names></name>
</person-group><article-title>Lithium Treatment Over the Lifespan in Bipolar Disorders</article-title><source>Front. Psychiatry</source><year>2020</year><volume>11</volume><elocation-id>377</elocation-id><pub-id pub-id-type="doi">10.3389/fpsyt.2020.00377</pub-id><pub-id pub-id-type="pmid">32457664</pub-id>
</element-citation></ref><ref id="B17-pharmaceuticals-18-00269"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Tabachnick</surname><given-names>B.G.</given-names></name>
<name><surname>Fidell</surname><given-names>L.S.</given-names></name>
<name><surname>Ullman</surname><given-names>J.B.</given-names></name>
</person-group><source>Using Multivariate Statistics</source><publisher-name>Pearson</publisher-name><publisher-loc>Boston, MA, USA</publisher-loc><year>2013</year><volume>Volume 6</volume><fpage>497</fpage><lpage>516</lpage></element-citation></ref><ref id="B18-pharmaceuticals-18-00269"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mardia</surname><given-names>K.V.</given-names></name>
</person-group><article-title>Measures of Multivariate Skewness and Kurtosis with Applications</article-title><source>Biometrika</source><year>1970</year><volume>57</volume><fpage>519</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1093/biomet/57.3.519</pub-id></element-citation></ref><ref id="B19-pharmaceuticals-18-00269"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Mardia</surname><given-names>K.V.</given-names></name>
<name><surname>Kent</surname><given-names>J.T.</given-names></name>
<name><surname>Taylor</surname><given-names>C.C.</given-names></name>
</person-group><source>Multivariate Analysis</source><publisher-name>John Wiley &#x00026; Sons</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2024</year><volume>Volume 88</volume></element-citation></ref><ref id="B20-pharmaceuticals-18-00269"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koukopoulos</surname><given-names>A.</given-names></name>
<name><surname>Reginaldi</surname><given-names>D.</given-names></name>
<name><surname>Tondo</surname><given-names>L.</given-names></name>
<name><surname>Visioli</surname><given-names>C.</given-names></name>
<name><surname>Baldessarini</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Course sequences in bipolar disorder: Depressions preceding or following manias or hypomanias</article-title><source>J. Affect. Disord.</source><year>2013</year><volume>151</volume><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2013.05.059</pub-id><pub-id pub-id-type="pmid">23827534</pub-id>
</element-citation></ref><ref id="B21-pharmaceuticals-18-00269"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kotzalidis</surname><given-names>G.D.</given-names></name>
<name><surname>Rapinesi</surname><given-names>C.</given-names></name>
<name><surname>Savoja</surname><given-names>V.</given-names></name>
<name><surname>Cuomo</surname><given-names>I.</given-names></name>
<name><surname>Simonetti</surname><given-names>A.</given-names></name>
<name><surname>Ambrosi</surname><given-names>E.</given-names></name>
<name><surname>Panaccione</surname><given-names>I.</given-names></name>
<name><surname>Gubbini</surname><given-names>S.</given-names></name>
<name><surname>De Rossi</surname><given-names>P.</given-names></name>
<name><surname>De Chiara</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Neurobiological evidence for the primacy of mania hypothesis</article-title><source>Curr. Neuropharmacol.</source><year>2017</year><volume>15</volume><fpage>339</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.2174/1570159X14666160708231216</pub-id><pub-id pub-id-type="pmid">28503105</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-18-00269"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maj</surname><given-names>M.</given-names></name>
<name><surname>Pirozzi</surname><given-names>R.</given-names></name>
<name><surname>Starace</surname><given-names>F.</given-names></name>
</person-group><article-title>Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients</article-title><source>J. Affect. Disord.</source><year>1989</year><volume>17</volume><fpage>237</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1016/0165-0327(89)90005-0</pub-id><pub-id pub-id-type="pmid">2529291</pub-id>
</element-citation></ref><ref id="B23-pharmaceuticals-18-00269"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rybakowski</surname><given-names>J.K.</given-names></name>
<name><surname>Dembinska</surname><given-names>D.</given-names></name>
<name><surname>Kliwicki</surname><given-names>S.</given-names></name>
<name><surname>Akiskal</surname><given-names>K.K.</given-names></name>
<name><surname>Akiskal</surname><given-names>H.H.</given-names></name>
</person-group><article-title>TEMPS-A and long-term lithium response: Positive correlation with hyperthymic temperament</article-title><source>J. Affect. Disord.</source><year>2013</year><volume>145</volume><fpage>187</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2012.07.028</pub-id><pub-id pub-id-type="pmid">22939170</pub-id>
</element-citation></ref><ref id="B24-pharmaceuticals-18-00269"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Azorin</surname><given-names>J.M.</given-names></name>
<name><surname>Adida</surname><given-names>M.</given-names></name>
<name><surname>Belzeaux</surname><given-names>R.</given-names></name>
</person-group><article-title>Predominant polarity in bipolar disorders: Further evidence for the role of affective temperaments</article-title><source>J. Affect. Disord.</source><year>2015</year><volume>182</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2015.04.037</pub-id><pub-id pub-id-type="pmid">25973784</pub-id>
</element-citation></ref><ref id="B25-pharmaceuticals-18-00269"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scott</surname><given-names>J.</given-names></name>
<name><surname>Bellivier</surname><given-names>F.</given-names></name>
<name><surname>Manchia</surname><given-names>M.</given-names></name>
<name><surname>Schulze</surname><given-names>T.</given-names></name>
<name><surname>Alda</surname><given-names>M.</given-names></name>
<name><surname>Etain</surname><given-names>B.</given-names></name>
<collab>Investigators involved in the ConLiGen collaboration</collab>
</person-group><article-title>Can network analysis shed light on predictors of lithium response in bipolar I disorder?</article-title><source>Acta Psychiatr. Scand.</source><year>2020</year><volume>141</volume><fpage>522</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1111/acps.13163</pub-id><pub-id pub-id-type="pmid">32068882</pub-id>
</element-citation></ref><ref id="B26-pharmaceuticals-18-00269"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Perugi</surname><given-names>G.</given-names></name>
<name><surname>Maremmani</surname><given-names>I.</given-names></name>
<name><surname>Toni</surname><given-names>C.</given-names></name>
<name><surname>Madaro</surname><given-names>D.</given-names></name>
<name><surname>Mata</surname><given-names>B.</given-names></name>
<name><surname>Akiskal</surname><given-names>H.S.</given-names></name>
</person-group><article-title>The contrasting influence of depressive hyperthymic temperaments on psychometrically derived manic subtypes</article-title><source>Psychiatry Res.</source><year>2001</year><volume>101</volume><fpage>249</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/S0165-1781(01)00232-3</pub-id><pub-id pub-id-type="pmid">11311928</pub-id>
</element-citation></ref><ref id="B27-pharmaceuticals-18-00269"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Janiri</surname><given-names>D.</given-names></name>
<name><surname>Simonetti</surname><given-names>A.</given-names></name>
<name><surname>Piras</surname><given-names>F.</given-names></name>
<name><surname>Ciullo</surname><given-names>V.</given-names></name>
<name><surname>Spalletta</surname><given-names>G.</given-names></name>
<name><surname>Sani</surname><given-names>G.</given-names></name>
</person-group><article-title>Predominant polarity and hippocampal subfield volumes in Bipolar disorders</article-title><source>Bipolar Disord.</source><year>2020</year><volume>22</volume><fpage>490</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1111/bdi.12857</pub-id><pub-id pub-id-type="pmid">31630469</pub-id>
</element-citation></ref><ref id="B28-pharmaceuticals-18-00269"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cade</surname><given-names>J.F.J.</given-names></name>
</person-group><article-title>Lithium salts in the treatment of psychotic excitement</article-title><source>Med. J. Aust.</source><year>1949</year><volume>2</volume><fpage>349</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.5694/j.1326-5377.1949.tb36912.x</pub-id><pub-id pub-id-type="pmid">18142718</pub-id>
</element-citation></ref><ref id="B29-pharmaceuticals-18-00269"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Machado-Vieira</surname><given-names>R.</given-names></name>
<name><surname>Manji</surname><given-names>H.K.</given-names></name>
<name><surname>Zarate</surname><given-names>C.A.</given-names></name>
</person-group><article-title>The role of lithium in the treatment of bipolar disorder: Convergent evidence for neurotrophic effects as a unifying hypothesis</article-title><source>Bipolar Disord.</source><year>2009</year><volume>11</volume><issue>(Suppl. S2)</issue><fpage>92</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1111/j.1399-5618.2009.00714.x</pub-id><pub-id pub-id-type="pmid">19538689</pub-id>
</element-citation></ref><ref id="B30-pharmaceuticals-18-00269"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kao</surname><given-names>C.-Y.</given-names></name>
<name><surname>Hsu</surname><given-names>Y.-C.</given-names></name>
<name><surname>Liu</surname><given-names>J.-W.</given-names></name>
<name><surname>Lee</surname><given-names>D.-C.</given-names></name>
<name><surname>Chung</surname><given-names>Y.-F.</given-names></name>
<name><surname>Chiu</surname><given-names>I.-M.</given-names></name>
</person-group><article-title>The mood stabilizer valproate activates human FGF1 gene promoter through inhibiting HDAC and GSK-3 activities</article-title><source>J. Neurochem.</source><year>2013</year><volume>126</volume><fpage>4</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1111/jnc.12292</pub-id><pub-id pub-id-type="pmid">23647222</pub-id>
</element-citation></ref><ref id="B31-pharmaceuticals-18-00269"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abu-Hijleh</surname><given-names>F.A.</given-names></name>
<name><surname>Prashar</surname><given-names>S.</given-names></name>
<name><surname>Joshi</surname><given-names>H.</given-names></name>
<name><surname>Sharma</surname><given-names>R.</given-names></name>
<name><surname>Frey</surname><given-names>B.N.</given-names></name>
<name><surname>Mishra</surname><given-names>R.K.</given-names></name>
</person-group><article-title>Novel mechanism of action for the mood stabilizer lithium</article-title><source>Bipolar Disord.</source><year>2021</year><volume>23</volume><fpage>76</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1111/bdi.13019</pub-id><pub-id pub-id-type="pmid">33037686</pub-id>
</element-citation></ref><ref id="B32-pharmaceuticals-18-00269"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Evans</surname><given-names>L.</given-names></name>
<name><surname>Akiskal</surname><given-names>H.S.</given-names></name>
<name><surname>Keck</surname><given-names>P.E.</given-names></name>
<name><surname>McElroy</surname><given-names>S.L.</given-names></name>
<name><surname>Sadovnick</surname><given-names>A.D.</given-names></name>
<name><surname>Remick</surname><given-names>R.A.</given-names></name>
<name><surname>Kelsoe</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Familiality of temperament in bipolar disorder: Support for a genetic spectrum</article-title><source>J. Affect. Disord.</source><year>2005</year><volume>85</volume><fpage>153</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2003.10.015</pub-id><pub-id pub-id-type="pmid">15780686</pub-id>
</element-citation></ref><ref id="B33-pharmaceuticals-18-00269"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Greenwood</surname><given-names>T.A.</given-names></name>
<name><surname>Akiskal</surname><given-names>H.S.</given-names></name>
<name><surname>Akiskal</surname><given-names>K.K.</given-names></name>
<name><surname>Kelsoe</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Genome-wide Association Study of Temperament in Bipolar Disorder Reveals Significant Associations To Three Novel Loci</article-title><source>Biol. Psychiatry</source><year>2012</year><volume>72</volume><fpage>303</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2012.01.018</pub-id><pub-id pub-id-type="pmid">22365631</pub-id>
</element-citation></ref><ref id="B34-pharmaceuticals-18-00269"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hasseris</surname><given-names>S.</given-names></name>
<name><surname>Albi&#x000f1;ana</surname><given-names>C.</given-names></name>
<name><surname>Vilhjalmsson</surname><given-names>B.J.</given-names></name>
<name><surname>Mortensen</surname><given-names>P.B.</given-names></name>
<name><surname>&#x000d8;stergaard</surname><given-names>S.D.</given-names></name>
<name><surname>Musliner</surname><given-names>K.L.</given-names></name>
</person-group><article-title>Polygenic Risk and Episode Polarity Among Individuals With Bipolar Disorder</article-title><source>Am. J. Psychiatry</source><year>2023</year><volume>180</volume><fpage>200</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.22010003</pub-id><pub-id pub-id-type="pmid">36651623</pub-id>
</element-citation></ref><ref id="B35-pharmaceuticals-18-00269"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kelsoe</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Polygenic Polarity in Bipolar Disorder</article-title><source>Am. J. Psychiatry</source><year>2023</year><volume>180</volume><fpage>177</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.20230040</pub-id><pub-id pub-id-type="pmid">36855878</pub-id>
</element-citation></ref><ref id="B36-pharmaceuticals-18-00269"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hou</surname><given-names>L.</given-names></name>
<name><surname>Heilbronner</surname><given-names>U.</given-names></name>
<name><surname>Degenhardt</surname><given-names>F.</given-names></name>
<name><surname>Adli</surname><given-names>M.</given-names></name>
<name><surname>Akiyama</surname><given-names>K.</given-names></name>
<name><surname>Akula</surname><given-names>N.</given-names></name>
<name><surname>Ardau</surname><given-names>R.</given-names></name>
<name><surname>Arias</surname><given-names>B.</given-names></name>
<name><surname>Backlund</surname><given-names>L.</given-names></name>
<name><surname>Banzato</surname><given-names>C.E.M.</given-names></name>
<etal/>
</person-group><article-title>Genetic variants associated with response to lithium treatment in bipolar disorder: A genome-wide association study</article-title><source>Lancet</source><year>2016</year><volume>387</volume><fpage>1085</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)00143-4</pub-id><pub-id pub-id-type="pmid">26806518</pub-id>
</element-citation></ref><ref id="B37-pharmaceuticals-18-00269"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Papiol</surname><given-names>S.</given-names></name>
<name><surname>Schulze</surname><given-names>T.G.</given-names></name>
<name><surname>Heilbronner</surname><given-names>U.</given-names></name>
</person-group><article-title>Lithium response in bipolar disorder: Genetics, genomics, and beyond</article-title><source>Neurosci. Lett.</source><year>2022</year><volume>785</volume><fpage>136786</fpage><pub-id pub-id-type="doi">10.1016/j.neulet.2022.136786</pub-id><pub-id pub-id-type="pmid">35817312</pub-id>
</element-citation></ref><ref id="B38-pharmaceuticals-18-00269"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ou</surname><given-names>A.H.</given-names></name>
<name><surname>Rosenthal</surname><given-names>S.B.</given-names></name>
<name><surname>Adli</surname><given-names>M.</given-names></name>
<name><surname>Akiyama</surname><given-names>K.</given-names></name>
<name><surname>Akula</surname><given-names>N.</given-names></name>
<name><surname>Alda</surname><given-names>M.</given-names></name>
<name><surname>Amare</surname><given-names>A.T.</given-names></name>
<name><surname>Ardau</surname><given-names>R.</given-names></name>
<name><surname>Arias</surname><given-names>B.</given-names></name>
<name><surname>Aubry</surname><given-names>J.M.</given-names></name>
<etal/>
</person-group><article-title>Lithium response in bipolar disorder is associated with focal adhesion and PI3K-Akt networks: A multi-omics replication study</article-title><source>Transl. Psychiatry</source><year>2024</year><volume>14</volume><fpage>109</fpage><pub-id pub-id-type="doi">10.1038/s41398-024-02811-4</pub-id><pub-id pub-id-type="pmid">38395906</pub-id>
</element-citation></ref><ref id="B39-pharmaceuticals-18-00269"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carta</surname><given-names>M.G.</given-names></name>
<name><surname>Hardoy</surname><given-names>M.C.</given-names></name>
<name><surname>Cadeddu</surname><given-names>M.</given-names></name>
<name><surname>Murru</surname><given-names>A.</given-names></name>
<name><surname>Campus</surname><given-names>A.</given-names></name>
<name><surname>Morosini</surname><given-names>P.L.</given-names></name>
<name><surname>Gamma</surname><given-names>A.</given-names></name>
<name><surname>Angst</surname><given-names>J.</given-names></name>
</person-group><article-title>The accuracy of the Italian version of the Hypomania Checklist (HCL-32) for the screening of bipolar disorders and comparison with the Mood Disorder Questionnaire (MDQ) in a clinical sample</article-title><source>Clin. Pract. Epidemiol. Ment. Health</source><year>2006</year><volume>2</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1745-0179-2-2</pub-id><pub-id pub-id-type="pmid">16524481</pub-id>
</element-citation></ref><ref id="B40-pharmaceuticals-18-00269"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zimmerman</surname><given-names>M.</given-names></name>
<name><surname>Galione</surname><given-names>J.N.</given-names></name>
<name><surname>Chelminski</surname><given-names>I.</given-names></name>
<name><surname>Young</surname><given-names>D.</given-names></name>
<name><surname>Dalrymple</surname><given-names>K.</given-names></name>
</person-group><article-title>Psychiatric diagnoses in patients who screen positive on the Mood Disorder Questionnaire: Implications for using the scale as a case-finding instrument for bipolar disorder</article-title><source>Psychiatry Res.</source><year>2011</year><volume>185</volume><fpage>444</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2010.06.025</pub-id><pub-id pub-id-type="pmid">20656360</pub-id>
</element-citation></ref><ref id="B41-pharmaceuticals-18-00269"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paterniti</surname><given-names>S.</given-names></name>
<name><surname>Bisserbe</surname><given-names>J.-C.</given-names></name>
</person-group><article-title>Factors associated with false positives in MDQ screening for bipolar disorder: Insight into the construct validity of the scale</article-title><source>J. Affect. Disord.</source><year>2018</year><volume>238</volume><fpage>79</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2018.05.058</pub-id><pub-id pub-id-type="pmid">29864713</pub-id>
</element-citation></ref><ref id="B42-pharmaceuticals-18-00269"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stanton</surname><given-names>K.</given-names></name>
<name><surname>Watson</surname><given-names>D.</given-names></name>
</person-group><article-title>Explicating the structure and relations of the Mood Disorder Questionnaire: Implications for screening for bipolar and related disorders</article-title><source>J. Affect. Disord.</source><year>2017</year><volume>220</volume><fpage>72</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2017.05.046</pub-id><pub-id pub-id-type="pmid">28600930</pub-id>
</element-citation></ref><ref id="B43-pharmaceuticals-18-00269"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carpenter</surname><given-names>R.W.</given-names></name>
<name><surname>Stanton</surname><given-names>K.</given-names></name>
<name><surname>Emery</surname><given-names>N.N.</given-names></name>
<name><surname>Zimmerman</surname><given-names>M.</given-names></name>
</person-group><article-title>Positive and Negative Activation in the Mood Disorder Questionnaire: Associations With Psychopathology and Emotion Dysregulation in a Clinical Sample</article-title><source>Assessment</source><year>2020</year><volume>27</volume><fpage>219</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1177/1073191119851574</pub-id><pub-id pub-id-type="pmid">31137947</pub-id>
</element-citation></ref><ref id="B44-pharmaceuticals-18-00269"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scott</surname><given-names>K.</given-names></name>
<name><surname>O&#x02019;Donovan</surname><given-names>C.</given-names></name>
<name><surname>Brancati</surname><given-names>G.E.</given-names></name>
<name><surname>Cervantes</surname><given-names>P.</given-names></name>
<name><surname>Ardau</surname><given-names>R.</given-names></name>
<name><surname>Manchia</surname><given-names>M.</given-names></name>
<name><surname>Severino</surname><given-names>G.</given-names></name>
<name><surname>Rybakowski</surname><given-names>J.</given-names></name>
<name><surname>Tondo</surname><given-names>L.</given-names></name>
<name><surname>Grof</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Phenotypic clustering of bipolar disorder supports stratification by lithium responsiveness over diagnostic subtypes</article-title><source>Acta Psychiatr. Scand.</source><year>2024</year><volume>150</volume><fpage>91</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1111/acps.13692</pub-id><pub-id pub-id-type="pmid">38643982</pub-id>
</element-citation></ref><ref id="B45-pharmaceuticals-18-00269"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manchia</surname><given-names>M.</given-names></name>
<name><surname>Adli</surname><given-names>M.</given-names></name>
<name><surname>Akula</surname><given-names>N.</given-names></name>
<name><surname>Ardau</surname><given-names>R.</given-names></name>
<name><surname>Aubry</surname><given-names>J.</given-names></name>
<name><surname>Backlund</surname><given-names>L.</given-names></name>
<name><surname>Banzato</surname><given-names>C.</given-names></name>
<name><surname>Baune</surname><given-names>B.</given-names></name>
<name><surname>Bellivier</surname><given-names>F.</given-names></name>
<name><surname>Bengesser</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e65636</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0065636</pub-id><pub-id pub-id-type="pmid">23840348</pub-id>
</element-citation></ref><ref id="B46-pharmaceuticals-18-00269"><label>46.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>First</surname><given-names>M.B.</given-names></name>
<name><surname>Williams</surname><given-names>J.B.W.</given-names></name>
<name><surname>Karg</surname><given-names>R.S.</given-names></name>
<name><surname>Spitzer</surname><given-names>R.L.</given-names></name>
</person-group><source>Structured Clinical Interview for DSM-5 Disorders, Clinician Version (SCID-5-CV)</source><publisher-name>American Psychiatric Association</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2016</year></element-citation></ref><ref id="B47-pharmaceuticals-18-00269"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Janiri</surname><given-names>D.</given-names></name>
<name><surname>Rossi</surname><given-names>P.D.</given-names></name>
<name><surname>Kotzalidis</surname><given-names>G.D.</given-names></name>
<name><surname>Girardi</surname><given-names>P.</given-names></name>
<name><surname>Koukopoulos</surname><given-names>A.E.</given-names></name>
<name><surname>Reginaldi</surname><given-names>D.</given-names></name>
<name><surname>Dotto</surname><given-names>F.</given-names></name>
<name><surname>Manfredi</surname><given-names>G.</given-names></name>
<name><surname>Jollant</surname><given-names>F.</given-names></name>
<name><surname>Gorwood</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Psychopathological characteristics and adverse childhood events are differentially associated with suicidal ideation and suicidal acts in mood disorders</article-title><source>Eur. Psychiatry</source><year>2018</year><volume>53</volume><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.eurpsy.2018.05.009</pub-id><pub-id pub-id-type="pmid">29879623</pub-id>
</element-citation></ref><ref id="B48-pharmaceuticals-18-00269"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hardoy</surname><given-names>M.C.</given-names></name>
<name><surname>Cadeddu</surname><given-names>M.</given-names></name>
<name><surname>Murru</surname><given-names>A.</given-names></name>
<name><surname>Dell&#x02019;Osso</surname><given-names>B.</given-names></name>
<name><surname>Carpiniello</surname><given-names>B.</given-names></name>
<name><surname>Morosini</surname><given-names>P.L.</given-names></name>
<name><surname>Calabrese</surname><given-names>J.R.</given-names></name>
<name><surname>Carta</surname><given-names>M.G.</given-names></name>
</person-group><article-title>Validation of the Italian version of the &#x0201c;Mood Disorder Questionnaire&#x0201d; for the screening of bipolar disorders</article-title><source>Clin. Pract. Epidemiol. Ment. Health</source><year>2005</year><volume>1</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/1745-0179-1-8</pub-id><pub-id pub-id-type="pmid">16042762</pub-id>
</element-citation></ref><ref id="B49-pharmaceuticals-18-00269"><label>49.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Tabachnick</surname><given-names>B.G.</given-names></name>
<name><surname>Fidell</surname><given-names>L.S.</given-names></name>
</person-group><source>Using Multivariate Statistics</source><edition>7th ed.</edition><publisher-name>Pearson</publisher-name><publisher-loc>Boston, MA, USA</publisher-loc><year>2019</year></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceuticals-18-00269-f001"><label>Figure 1</label><caption><p>Raincloud plots illustrating the distribution of scores obtained by Lithium Non-Responders and Lithium Responders on (<bold>a</bold>) the Hypomania Checklist-32 (HCL-32) and (<bold>b</bold>) the Mood Disorder Questionnaire (MDQ). (<bold>c</bold>) Distributions of aggregate z-scores, computed across the HCL-32 and MDQ, are shown with corresponding box plots as a function of group classification into Lithium Non-Responders and Lithium Responders.</p></caption><graphic xlink:href="pharmaceuticals-18-00269-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00269-f002"><label>Figure 2</label><caption><p>Marginal effects of the linear regression analysis. The plot illustrates the relationships between the predictor variables (<bold>a</bold>) Gender, (<bold>b</bold>) Age, (<bold>c</bold>) HCL-32, and (<bold>d</bold>) MDQ and the Alda Scale scores, highlighting the estimated regression lines along with their confidence intervals.</p></caption><graphic xlink:href="pharmaceuticals-18-00269-g002" position="float"/></fig><table-wrap position="float" id="pharmaceuticals-18-00269-t001"><object-id pub-id-type="pii">pharmaceuticals-18-00269-t001_Table 1</object-id><label>Table 1</label><caption><p>Sociodemographic, clinical, and screening assessment of the sample according to lithium response (N = 146).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variables</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Lithium <break/> Responders <break/> (N = 46)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Lithium <break/> Non-Responders <break/> (N = 100)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">F or &#x003c7;<sup>2</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">df</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effect Size <break/> (&#x003b7;<sup>2</sup>&#x0209a; or &#x003c6;)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age, y&#x02014;mean &#x000b1; SD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43.60 &#x000b1; 13.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43.86 &#x000b1; 11.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.907</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.46 &#x000d7; 10<sup>&#x02212;5</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gender, N (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">&#x0003c;0.01</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.987</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.002</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (52.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">52 (52.0%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22 (47.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48 (48.0%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Education, y&#x02014;mean &#x000b1; SD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.67 &#x000b1; 3.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.25 &#x000b1; 3.49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.494</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Married, yes&#x02014;N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 (41.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45 (45.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.676</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.035</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coffee, yes&#x02014;N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36 (78.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78 (78.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c; 0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.972</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.003</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Smoking, yes&#x02014;N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 (50.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48 (48.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.822</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.019</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Family psychiatric history, yes&#x02014;N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33 (71.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68 (68.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.649</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.038</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospitalization, yes&#x02014;N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 (58.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70 (70.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.81</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.179</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.111</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body Mass Index, mean &#x000b1; SD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.67 &#x000b1; 4.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.84 &#x000b1; 3.68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.813</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.90 &#x000d7; 10<sup>&#x02212;4</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypomania Symptom Checklist-32 <break/> (HCL-32), mean &#x000b1; SD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.78 &#x000b1; 7.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.05 &#x000b1; 6.92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.023 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.051</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mood Disorder Questionnaire (MDQ), mean &#x000b1; SD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.76 &#x000b1; 2.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.30 &#x000b1; 3.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.403</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antidepressants, yes&#x02014;N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (15.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38 (38.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.760</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.006 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.223</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antipsychotics, yes&#x02014;N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26 (56.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78 (78.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.093</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.008 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.215</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiepileptics, yes&#x02014;N (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (39.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59 (59.0%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.991</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.025 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.182</td></tr></tbody></table><table-wrap-foot><fn><p>* <italic toggle="yes">p</italic> &#x0003c; 0.05; N, number of observations; df, degrees of freedom; y, years; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap></floats-group></article>